PAFAH1B3 and neoplasm: We observed that multiple clinicopathological analyses of PAFAH1B3 in the UALCAN database consistently showed the elevated transcription levels of PAFAH1B3 in HCC patients than healthy people in subgroup analyses based on age, gender, tumor grade, cancer stages, ethnicity and TP53 mutation (Table 2).